Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas

Pigment Cell and Melanoma Research

Volumn 26, Issue 5, 2013, Pages 646-653

  Niu, Hai Tao ^a,d   Zhou, Qi Ming ^b   Wang, Fang ^a   Shao, Qiong ^a   Guan, Yuan Xiang ^a   Wen, Xi Zhi ^a   Chen, Li Zhen ^a   Feng, Qi Sheng ^a   Li, Wei ^c   Zeng, Yi Xin ^a   Zhang, Xiao Shi ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b The 6th Affiliated Hospital of Shenzhen University Health Science Center   (China)

^c SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

^d CANCER HOSPITAL   (China)

Author keywords

Acral; ALK break point; Melanoma; Mucosal; Mutation

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ACRAL MELANOMA; ADULT; ARTICLE; CANCER STAGING; CHINA; ENZYME ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MELANOMA; MUCOSAL MELANOMA; ONCOGENE C KIT; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; REAL TIME POLYMERASE CHAIN REACTION; SOMATIC MUTATION;

ACRAL; ALK BREAK POINT; MELANOMA; MUCOSAL; MUTATION;

ADULT; AGED; CARCINOGENESIS; CHROMOSOME BREAKPOINTS; FEMALE; GENE REARRANGEMENT; GENOTYPING TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MASS SPECTROMETRY; MELANOMA; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; SKIN NEOPLASMS;

EID: 84883037696     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12129     Document Type: Article

References (36)

1. Bauer, J., Buttner, P., Murali, R., Okamoto, I., Kolaitis, N.A., Landi, M.T., Scolyer, R.A., and Bastian, B.C. (2011). BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 24, 345-351.
2. Beadling, C., Jacobson-Dunlop, E., Hodi, F.S. et al. (2008). KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 14, 6821-6828.
3. Butrynski, J.E., D'adamo, D.R., Hornick, J.L. et al. (2010). Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363, 1727-1733.
4. Carvajal, R.D., Antonescu, C.R., Wolchok, J.D. et al. (2011). KIT as a therapeutic target in metastatic melanoma. JAMA 305, 2327-2334.
5. Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
6. Chi, Z., Li, S., Sheng, X., Si, L., Cui, C., Han, M., and Guo, J. (2011). Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer 11, 85.
7. Cui, Q. (2010). A network of cancer genes with co-occurring and anti-co-occurring mutations. PLoS ONE 5.
8. Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147.
9. Daniels, A.B., Lee, J.E., Macconaill, L.E. et al. (2012). High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Invest. Ophthalmol. Vis. Sci. 53, 6991-6996.
10. Flaherty, K.T., and Mcarthur, G. (2010). BRAF, a target in melanoma: implications for solid tumor drug development. Cancer 116, 4902-4913.
11. Fumagalli, D., Gavin, P.G., Taniyama, Y., Kim, S.I., Choi, H.J., Paik, S., and Pogue-Geile, K.L. (2010). A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer 10, 101.
12. Gambacorti-Passerini, C., Messa, C., and Pogliani, E.M. (2011). Crizotinib in anaplastic large-cell lymphoma. N. Engl. J. Med. 364, 775-776.
13. Gerlinger, M., Rowan, A.J., Horswell, S. et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892.
14. Gottlieb, B., Alvarado, C., Wang, C., Gharizadeh, B., Babrzadeh, F., Richards, B., Batist, G., Basik, M., Beitel, L.K., and Trifiro, M. (2013). Making sense of intratumor genetic heterogeneity: altered frequency of androgen receptor CAG repeat length variants in breast cancer tissues. Hum. Mutat. 34, 610-618.
15. Guo, J., Si, L., Kong, Y. et al. (2011). Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J. Clin. Oncol. 29, 2904-2909.
16. Kobayashi, S., Boggon, T.J., Dayaram, T., Janne, P.A., Kocher, O., Meyerson, M., Johnson, B.E., Eck, M.J., Tenen, D.G., and Halmos, B. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792.
17. Koivunen, J.P., Mermel, C., Zejnullahu, K. et al. (2008). EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14, 4275-4283.
18. Kong, Y., Si, L., Zhu, Y. et al. (2011). Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin. Cancer Res. 17, 1684-1691.
19. Kwak, E.L., Bang, Y.J., Camidge, D.R. et al. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703.
20. Mao, M., Tian, F., Mariadason, J.M. et al. (2013). Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin. Cancer Res. 19, 657-667.
21. Park, H.S., Lee, J.K., Kim, D.W., Kulig, K., Kim, T.M., Lee, S.H., Jeon, Y.K., Chung, D.H., and Heo, D.S. (2012). Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 77, 288-292.
22. Puri, N., Ahmed, S., Janamanchi, V., Tretiakova, M., Zumba, O., Krausz, T., Jagadeeswaran, R., and Salgia, R. (2007). c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin. Cancer Res. 13, 2246-2253.
23. Qi, R.Q., He, L., Zheng, S. et al. (2011). BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han. J. Invest. Dermatol. 131, 1129-1138.
24. Sanders, H.R., Li, H.R., Bruey, J.M., Scheerle, J.A., Meloni-Ehrig, A.M., Kelly, J.C., Novick, C., and Albitar, M. (2011). Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet. 204, 45-52.
25. Shaw, A.T., Yeap, B.Y., Mino-Kenudson, M. et al. (2009). Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247-4253.
26. Si, L., Kong, Y., Xu, X., Flaherty, K.T., Sheng, X., Cui, C., Chi, Z., Li, S., Mao, L., and Guo, J. (2012). Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur. J. Cancer 48, 94-100.
27. Smalley, K.S., Xiao, M., Villanueva, J. et al. (2009). CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28, 85-94.
28. Soda, M., Choi, Y.L., Enomoto, M. et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566.
29. Sosman, J.A., Kim, K.B., Schuchter, L. et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714.
30. Thomas, R.K., Baker, A.C., Debiasi, R.M. et al. (2007). High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347-351.
31. Tyner, J.W., Fletcher, L.B., Wang, E.Q. et al. (2010). MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res. 70, 6233-6237.
32. Wang, R., Pan, Y., Li, C. et al. (2012). The use of quantitative real-time reverse transcriptase PCR for 5′ and 3′ portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin. Cancer Res. 18, 4725-4732.
33. Whitwam, T., Vanbrocklin, M.W., Russo, M.E., Haak, P.T., Bilgili, D., Resau, J.H., Koo, H.M., and Holmen, S.L. (2007). Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene 26, 4563-4570.
34. Wood, L.D., Parsons, D.W., Jones, S. et al. (2007). The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113.
35. Yang, H., Higgins, B., Kolinsky, K. et al. (2010). RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518-5527.
36. Zhou, Q.M., Li, W., Zhang, X. et al. (2012). The mutation profiles of common oncogenes involved in melanoma in southern China. J. Invest. Dermatol. 132, 1935-1937.